Drug Approval Reforms Ineffective Without Payer Reforms, Tunis Argues
Executive Summary
Granting payers more conditional coverage authority may be necessary for legislation to succeed at accelerating biomedical innovation, the former CMS CMO argues, but industry may not be on board.